Breast Cancer Research and Treatment

, Volume 160, Issue 3, pp 425–437 | Cite as

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials

  • Fausto Petrelli
  • Sandro Barni
  • Giacomo Bregni
  • Filippo de Braud
  • Serena Di Cosimo



The interest in platinum salts in breast cancer (BC) therapy has been recently renewed as inhibition of DNA damage response may enhance the effects of DNA-damaging agents in BC tumors with high genomic instability. The present systematic review and meta-analysis of randomized trials were performed to assess the efficacy and safety of therapy with platinum salts in patients with locally advanced or metastatic (hereinafter advanced) BC.


We searched PubMed, EMBASE, SCOPUS, Web of Science, the Cochrane Library, and CINAHL for phase II/III clinical trials that assessed efficacy of platinum-based therapy in patients with advanced BC. Pooled estimates of overall response rate (RR), median progression-free survival (PFS) and overall survival (OS) were computed using random or fixed effects models.


Data on 4625 patients from 23 phase II and III trials (11 with cisplatin, 11 with carboplatin, and 1 with either agents respectively) were analyzed. Estimates for RR, PFS, and OS were obtained from 23, 13, and 15 studies, respectively. Although at the cost of significantly increased fatigue, hematological and gastrointestinal toxicity, compared with non-platinum schemas, cisplatin, and carboplatin prolonged OS (HR 0.91; 95 % CI 0.83–1.00, p = 0.04), PFS (HR 0.84; 95 % CI 0.73–0.97, p = 0.01), and RR (HR 1.27; 95 % CI 1.03–1.57, p = 0.03).


Despite some limitations of the studies examined, including partial information on hormonal receptor and HER2 status, the use of platinum salts significantly prolonged OS, and PFS of patients with advanced BC with no unexpected toxicity.


Advanced breast cancer Cisplatinum Carboplatinum Meta-analysis Survival 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    McCutcheon S, Cardoso F (2015) Challenges in optimizing care in advanced BC patients: results of an international survey linked to the ABC1 consensus conference. Breast 24:623–629CrossRefPubMedGoogle Scholar
  2. 2.
    Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S (2014) The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 144:223–232CrossRefPubMedGoogle Scholar
  3. 3.
    Guan X, Ma F, Fan Y, Zhu W, Hong R, Xu B (2015) Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anticancer Drugs 26:894–901CrossRefPubMedGoogle Scholar
  4. 4.
    Carrick S, Ghersi D, Wilcken N, Simes J (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003374.pub3
  5. 5.
    Hu XC, Zhang J, Xu BH et al (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:436–446. doi: 10.1016/S1470-2045(15)70064-1 CrossRefPubMedGoogle Scholar
  6. 6.
    von Minckwitz G, Schneeweiss A, Loibl S et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756CrossRefGoogle Scholar
  7. 7.
    Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y (2014) Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 145:401–409CrossRefPubMedGoogle Scholar
  8. 8.
    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284CrossRefPubMedGoogle Scholar
  9. 9.
    Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349:g7647CrossRefPubMedGoogle Scholar
  11. 11.
    Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
  13. 13.
    Deeks JJ, Higgins JP, Altman DG (2011) Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, ChichesterGoogle Scholar
  14. 14.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMedGoogle Scholar
  15. 15.
    Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Marschke RF (1984) A phase III trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 2:1260–1265PubMedGoogle Scholar
  17. 17.
    Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M (1991) Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 9:664–669PubMedGoogle Scholar
  18. 18.
    Cocconi G, Bisagni G, Ceci G, Di Blasio B, De Lisi V, Passalacqua R, Zadro A, Boni C, Morandi P, Savoldi L (1999) Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. Breast Cancer Res Treat 56:125–132CrossRefPubMedGoogle Scholar
  19. 19.
    Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL (1999) Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642. J Clin Oncol 17:1397–1406PubMedGoogle Scholar
  20. 20.
    Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT, Walsh G, Ashley S (1998) Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 16:1350–1357PubMedGoogle Scholar
  21. 21.
    Icli F, Akbulut H, Uner A et al (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomized phase III trial of Turkish Oncology Group. Br J Cancer 92:639–644. doi: 10.1038/sj.bjc.6602388 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Berruti A, Bitossi R, Gorzegno G et al (2002) Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 20:4150–4159. doi: 10.1200/JCO.2002.08.012 CrossRefPubMedGoogle Scholar
  23. 23.
    Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517–1526. doi: 10.1093/annonc/mdh395 CrossRefPubMedGoogle Scholar
  24. 24.
    Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T (2000) Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 46:459–466CrossRefPubMedGoogle Scholar
  25. 25.
    Fountzilas G, Dafni U, Dimopoulos MA et al (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. Breast Cancer Res Treat 115:87–99. doi: 10.1007/s10549-008-0047-9 CrossRefPubMedGoogle Scholar
  26. 26.
    Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792. doi: 10.1200/JCO.2005.04.1764 CrossRefPubMedGoogle Scholar
  27. 27.
    Frasci G, D’Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 95:1005–1012. doi: 10.1038/sj.bjc.6603395 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG (2013) Docetaxel-cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 24:1219–1225. doi: 10.1093/annonc/mds603 CrossRefPubMedGoogle Scholar
  29. 29.
    Xu B, Jiang Z, Kim SB, Yu S, Feng J, Malzyner A, del Giglio A, Chung HC, Shen LJ, Pen DLK (2011) Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer 18:203–212. doi: 10.1007/s12282-011-0260-y CrossRefPubMedGoogle Scholar
  30. 30.
    Stemmler HJ, diGioia D, Freier W, Tessen HW, Gitsch G, Jonat W, Brugger W, Kettner E, Abenhardt W, Tesch H, Hurtz HJ, Rosel S, Brudler O, Heinemann V (2011) Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer 104:1071–1078. doi: 10.1038/bjc.2011.86 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156. doi: 10.1200/JCO.2010.28.6450 CrossRefPubMedGoogle Scholar
  32. 32.
    Huang L, Chen S, Yang W et al (2015) Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II–III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget 6:18683–18692CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Carey LA, Rugo HS, Marcom PK et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30:2615–2623. doi: 10.1200/JCO.2010.34.5579 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Alba E, Chacon JI, Lluch A et al (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:487–493. doi: 10.1007/s10549-012-2100-y CrossRefPubMedGoogle Scholar
  35. 35.
    Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N (2013) Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD008792.pub2

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Fausto Petrelli
    • 1
  • Sandro Barni
    • 1
  • Giacomo Bregni
    • 2
  • Filippo de Braud
    • 3
  • Serena Di Cosimo
    • 4
  1. 1.Medical Oncology UnitASST Bergamo OvestTreviglioItaly
  2. 2.Department of Medical OncologyIRCCS A.O.U. S.Martino-ISTGenoaItaly
  3. 3.University of Milan, Fondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  4. 4.Division of OncologyFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly

Personalised recommendations